AdvanCell
AdvanCell develops targeted alpha radiopharmaceuticals for cancer using Lead-212, with integrated isotope supply and manufacturing.
$315MSeries D
Role not disclosedAB
Ally Bridge Group
Activity from announced rounds
Activity in this selectionnomura-real-estate-development-co-f095adde
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $455M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionCalyxo
Develops medical devices for kidney stone treatment and removal
$40MSeries F
Role not disclosedImperative Care
Develops treatments for patients suffering from thromboembolic disease
$100MGrowth
Role not disclosed